Janux Therapeutics Inc (JANX) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Janux Therapeutics Inc

NASDAQ | JANX

26.99

USD

-1.26 (-4.46%)

AT CLOSE (AS OF Apr 3, 2025)

$1.7B

MARKET CAP

P/E Ratio

-1.28

EPS

$72

52 Week High

$26

52 Week Low

LIFE SCIENCES

Sector

JANX Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

JANX Technicals

Tags:

JANX Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$15M
Total Revenue	$11M
Cost Of Revenue	$26M
Costof Goods And Services Sold	$2M
Operating Income	-$73M
Selling General And Administrative	$26M
Research And Development	$55M
Operating Expenses	$107M
Investment Income Net	-
Net Interest Income	$13M
Interest Income	$13M
Interest Expense	-
Non Interest Income	$8.1M
Other Non Operating Income	-
Depreciation	$2M
Depreciation And Amortization	$2M
Income Before Tax	-$58M
Income Tax Expense	$0
Interest And Debt Expense	-
Net Income From Continuing Operations	-$58M
Comprehensive Income Net Of Tax	-$56M
Ebit	-$73M
Ebitda	-$71M
Net Income	-$58M

Revenue & Profitability

Earnings Performance

JANX Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (USD)
Total Assets	$380M
Total Current Assets	$349M
Cash And Cash Equivalents At Carrying Value	$19M
Cash And Short Term Investments	$344M
Inventory	-$2.2M
Current Net Receivables	$2.2M
Total Non Current Assets	$31M
Property Plant Equipment	$7M
Accumulated Depreciation Amortization Ppe	$2.9M
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	$325M
Long Term Investments	-
Short Term Investments	$325M
Other Current Assets	$5.2M
Other Non Current Assets	$2.5M
Total Liabilities	$36M
Total Current Liabilities	$13M
Current Accounts Payable	$2.4M
Deferred Revenue	$1.7M
Current Debt	-
Short Term Debt	$1.5M
Total Non Current Liabilities	$23M
Capital Lease Obligations	$25M
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$25M
Other Current Liabilities	$7.4M
Other Non Current Liabilities	-
Total Shareholder Equity	$344M
Treasury Stock	-
Retained Earnings	-$169M
Common Stock	$46K
Common Stock Shares Outstanding	$46M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	-$51M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-$401K
Change In Operating Assets	$909K
Depreciation Depletion And Amortization	-$5.7M
Capital Expenditures	$1.9M
Change In Receivables	-
Change In Inventory	-
Profit Loss	-$58M
Cashflow From Investment	-$41M
Cashflow From Financing	$60M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$58M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$15M
Total Revenue	$11M
Cost Of Revenue	$26M
Costof Goods And Services Sold	$2M
Operating Income	-$73M
Selling General And Administrative	$26M
Research And Development	$55M
Operating Expenses	$107M
Investment Income Net	-
Net Interest Income	$13M
Interest Income	$13M
Interest Expense	-
Non Interest Income	$8.1M
Other Non Operating Income	-
Depreciation	$2M
Depreciation And Amortization	$2M
Income Before Tax	-$58M
Income Tax Expense	$0
Interest And Debt Expense	-
Net Income From Continuing Operations	-$58M
Comprehensive Income Net Of Tax	-$56M
Ebit	-$73M
Ebitda	-$71M
Net Income	-$58M

JANX Profile

Janux Therapeutics Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217
PTIX	$0.43	91.50%	$4.04M	173,208,693

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.60	-0.95%	$308.32B	7,033,051
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	20,249,631
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

JANX $26.99 (-4.46%) Quote details